Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2026
Clinical Characteristics and Visual Outcomes of Optic Neuritis in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdul Takhmina, Nisanova Arina, Chopra Anjalee, Bugsch Ryan, Virupakshaiah Akash, Kothapalli Naga Pradyumna, Panse Ketaki Milind, Waubant Emmanuelle, Rasool Nailyn, Beres Shannon J, Liu Yin Allison
Аннотация
BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a neuro-immunological disorder that can cause optic neuritis (ON) and significant visual impairment. Our objective was to investigate clinical characteristics and visual outcomes in children with MOGAD-ON.
METHODS: Retrospective cohort study of MOG-IgG-positive children (onset age 18 years and younger) meeting 2023 international MOGAD panel criteria who presented with ON and received neuro-ophthalmic care between 2003 and 2023 at 3 academic centers in Northern California was conducted. We captured demographic and clinical characteristics, disease course, and presenting MOG-IgG titers through chart review. Ophthalmic metrics, including logarithmic minimum angle of resolution best-corrected visual acuity (logMAR BCVA), retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer thicknesses, and automated visual field mean deviation (AVF MD) at diagnosis, 1-month, 6-month, 1-year, and final (2+ years) visits, were obtained.
RESULTS: This study included 49 ON-affected eyes of 29 patients (20 with bilateral involvement), with 19 (66%) being female. The median age at first diagnosis was 9 years (range 1-18). The median follow-up was 40 months (0-119). Age younger than 8 years at MOGAD onset was predictive of recurrent ON (β1=-1.61, P = 0.03). LogMAR BCVA improved from 1.4 at diagnosis to 0.2 at 1 month and 0.07 at the final visit (P < 0.0001). In total, 29 eyes (59%) of 22 patients (76%) achieved complete visual recovery (BCVA LogMAR 0). RNFL thickness decreased from mean 130 µm at diagnosis to 6 months (65 µm, P < 0.05). Average AVF MD improved from -12.8 dB at diagnosis to -5.4 dB at the final visit (P = 0.02). Higher presenting MOG-IgG titers were associated with worse presenting visual fields (r = -0.96, P = 0.04).
CONCLUSIONS: Children with MOGAD-associated ON often return to normal visual acuity despite significant optic atrophy. Most RNFL thinning occurs in the first 6 months but continues beyond 2 years after MOGAD onset. Younger children were at greater risk of ON relapse. A prospective longitudinal study on pediatric MOGAD-ON is warranted to validate these findings and identify biomarkers for visual outcome prediction.
METHODS: Retrospective cohort study of MOG-IgG-positive children (onset age 18 years and younger) meeting 2023 international MOGAD panel criteria who presented with ON and received neuro-ophthalmic care between 2003 and 2023 at 3 academic centers in Northern California was conducted. We captured demographic and clinical characteristics, disease course, and presenting MOG-IgG titers through chart review. Ophthalmic metrics, including logarithmic minimum angle of resolution best-corrected visual acuity (logMAR BCVA), retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer thicknesses, and automated visual field mean deviation (AVF MD) at diagnosis, 1-month, 6-month, 1-year, and final (2+ years) visits, were obtained.
RESULTS: This study included 49 ON-affected eyes of 29 patients (20 with bilateral involvement), with 19 (66%) being female. The median age at first diagnosis was 9 years (range 1-18). The median follow-up was 40 months (0-119). Age younger than 8 years at MOGAD onset was predictive of recurrent ON (β1=-1.61, P = 0.03). LogMAR BCVA improved from 1.4 at diagnosis to 0.2 at 1 month and 0.07 at the final visit (P < 0.0001). In total, 29 eyes (59%) of 22 patients (76%) achieved complete visual recovery (BCVA LogMAR 0). RNFL thickness decreased from mean 130 µm at diagnosis to 6 months (65 µm, P < 0.05). Average AVF MD improved from -12.8 dB at diagnosis to -5.4 dB at the final visit (P = 0.02). Higher presenting MOG-IgG titers were associated with worse presenting visual fields (r = -0.96, P = 0.04).
CONCLUSIONS: Children with MOGAD-associated ON often return to normal visual acuity despite significant optic atrophy. Most RNFL thinning occurs in the first 6 months but continues beyond 2 years after MOGAD onset. Younger children were at greater risk of ON relapse. A prospective longitudinal study on pediatric MOGAD-ON is warranted to validate these findings and identify biomarkers for visual outcome prediction.